Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:cytokine
gptkb:protein |
| gptkbp:administeredBy |
injection
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:L03AB
|
| gptkbp:CASNumber |
9008-11-1
|
| gptkbp:contraindication |
autoimmune hepatitis
decompensated liver disease severe psychiatric disorders |
| gptkbp:discoveredBy |
gptkb:Jean_Lindenmann
gptkb:Alick_Isaacs |
| gptkbp:discoveredIn |
1957
|
| gptkbp:encodedBy |
IFNA genes
|
| gptkbp:foundIn |
blood plasma
|
| gptkbp:halfLife |
2-3 hours
|
| gptkbp:inducedBy |
apoptosis in infected cells
immune cell activation expression of antiviral proteins |
| gptkbp:marketedAs |
gptkb:Infergen
gptkb:Roferon-A Intron A |
| gptkbp:mechanismOfAction |
inhibits viral replication
modulates immune response increases expression of MHC class I molecules induces antiviral state in cells |
| gptkbp:pregnancyCategory |
C
|
| gptkbp:producedBy |
gptkb:leukocytes
|
| gptkbp:promotion |
gptkb:virus
double-stranded RNA bacterial products |
| gptkbp:proteinFamily |
gptkb:type_I_interferons
|
| gptkbp:recipient |
gptkb:interferon_alpha/beta_receptor
|
| gptkbp:sideEffect |
gptkb:depression
autoimmune disorders fatigue myelosuppression flu-like symptoms |
| gptkbp:species |
gptkb:human
gptkb:mouse other mammals |
| gptkbp:structure |
single-chain polypeptide
|
| gptkbp:UNII |
6G8XRS6194
|
| gptkbp:usedFor |
treatment of certain cancers
treatment of hepatitis C treatment of chronic myelogenous leukemia treatment of hepatitis B treatment of Kaposi's sarcoma treatment of hairy cell leukemia treatment of malignant melanoma |
| gptkbp:bfsParent |
gptkb:natural_killer_cells
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
interferon-alpha
|